English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduRutgers Cancer Institute of New Jersey expert addresses what you should know about pancreatic cancer including risks, symptoms and treatment.
Tag: Pancreatic Cancer
New Research in JNCCN Evaluates Cost-Effectiveness of Olaparib, a PARP Inhibitor, for Metastatic Pancreatic Cancer
New research in the November 2020 issue of JNCCN identifies metastatic pancreatic cancer patient subgroups with the highest relative cost-effectiveness from maintenance olaparib, a PARP inhibitor.
Expert alert: Changing the outlook for pancreatic cancer
Pancreatic cancer often is hidden and doesn’t cause symptoms until it has spread. It is a leading cause of cancer deaths in the world.
November 19 is World Pancreatic Cancer Day, but the entire month of November is meant to bring awareness to this disease.
Advances in screening and early detection for high-risk people, minimally invasive surgical innovations and new genetic classifications are changing the outlook for pancreatic cancer, says Dr. Michael Wallace, a Mayo Clinic gastroenterologist.
Learning more about Pancreatic Cancer
With the recent passing of Jeopardy host Alex Trebek, Rutgers Cancer Institute of New Jersey expert explains pancreatic cancer and the progress being made with this disease through research and clinical trials.
UCLA pancreatic cancer surgeon/expert to speak on the death of Alex Trebek
In mourning of the death of Alex Trebek,Timothy Donahue, MD, chief of surgical oncology at UCLA’s Jonsson Comprehensive Cancer Center is available to discuss complications from metastatic cancer of the pancreas and the advances in treatment for pancreatic cancer. More…
Moderate-pace Walking Shrunk Pancreatic Cancer Tumors and Increased Cancer-killing Cells, Small Study Shows
Emily LaVoy, PhD, of the University of Houston, and colleagues explored the effects of moderate-intensity exercise on a mouse model of pancreatic cancer. Pancreatic cancer can be a particularly dangerous form of cancer because it is often diagnosed in later stages and spreads quickly. Though the trial sample was small—thus warranting further study—the results were optimistic.
Nerves Keep Pancreatic Cancer Cells from Starving
Pancreatic cancer cells avert starvation by signaling to nerves, which grow into dense tumors and secrete nutrients.
New Map of the Immune Landscape in Pancreatic Cancer Could Guide Future Personalized Immunotherapy Treatments
A new analysis highlights the diversity of immune response in pancreatic cancer, and points toward the need for treatments tailored to individual patients.
New experimental blood test determines which pancreatic cancers will respond to treatment
GRAND RAPIDS, Mich. (Oct. 22, 2020) — Scientists have developed a simple, experimental blood test that distinguishes pancreatic cancers that respond to treatment from those that do not. This critical distinction could one day guide therapeutic decisions and spare patients with resistant cancers from undergoing unnecessary treatments with challenging side effects.
Deirdre J. Cohen, MD, MS, Appointed as Director of Gastrointestinal Oncology Program of Mount Sinai Health System
Deirdre J. Cohen, MD, MS, an expert in pancreatic and other gastrointestinal cancers as well as an accomplished clinical trial leader has joined Mount Sinai Health System as Director of the Gastrointestinal (GI) Oncology Program and Medical Director of the Cancer Clinical Trials Office at The Tisch Cancer Institute.
Hackensack Meridian CDI Scientists Find One-Two Punch Working against Stubborn Pancreatic Cancer in Preclinical Models
Changing gene expression, then deploying immune checkpoint inhibitors, shows promise in battling one of the most treatment-resistant types of cancer in preclinical models
UCLA pancreatic cancer surgeon/expert to speak on the death of Supreme Court Justice Ruth Badger Ginsburg
In mourning of the death of Supreme Court Justice Ruth Badger Ginsburg,Timothy Donahue, MD, chief of surgical oncology at UCLA’s Jonsson Comprehensive Cancer Center is available to discuss complications from metastatic cancer of the pancreas and the advances in treatment…
Pancreatic cancer physician available to discuss medical conditions in wake of RBG passing
Bart Rose, M.D. Department of Surgery Areas of expertise: Pancreatic cancer Diseases of the stomach Rose is director of the UAB Pancreatobiliary Disease Center — the first multidisciplinary program in the Alabama to treat diseases of the pancreas and bile…
Small Change makes Cancer Vaccine More Effective in Animal Tests
Tweaking the adenovirus spike protein induces a more robust immune reaction for a cancer vaccine against gastric, pancreatic, esophageal and colon malignancies in animal models.
Scientists discover novel drug target for pancreatic cancer
Scientists at Sanford Burnham Prebys Medical Discovery Institute have uncovered a novel drug target, a protein called PPP1R1B, that stops the deadly spread of pancreatic cancer, called metastasis, when inhibited in mice. Published in Gastroenterology, the findings are a first step toward a potential treatment for one of the deadliest cancers known today.
UC Davis Health expert available to discuss pancreatic cancer: Why it is so lethal, and why there is hope
UC Davis Health expert available to discuss pancreatic cancer: Why it is so lethal, and why there is hope The passing of Congressman John Lewis and recent update from Jeopardy host Alex Trebek renew focus on this rare but…
Study Suggests Method to Starve Pancreatic Cancer Cells
Rather than attacking cancer cells directly, new cell-model research probes weaknesses in pancreatic cancer’s interactions with other cells to obtain nutrients needed for tumor growth.
Preventing pancreatic cancer metastasis by keeping cells “sheltered in place”
Scientists at Sanford Burnham Prebys Medical Discovery Institute have shown that pancreatic cancer metastasis—when tumor cells gain the deadly ability to migrate to new parts of the body—can be suppressed by inhibiting a protein called Slug that regulates cell movement. The study, published in the Journal of Experimental Medicine, also revealed two druggable targets that interact with Slug and hold promise as treatments that may stop the spread of pancreatic cancer.
Researchers identify therapeutic targets to prevent cancer-associated muscle loss
Researchers at the University of Nebraska Medical Center have identified a key cell signaling pathway that drives the devastating muscle loss, or cachexia, suffered by many cancer patients. The study, which will be published May 22 in the Journal of Experimental Medicine, suggests that targeting this pathway with a drug already in phase 2 clinical trials for diabetes could prevent this syndrome.
$5.75M grant to help researchers study role of obesity in development of pancreatic cancer
A team of researchers from the UCLA Jonsson Comprehensive Cancer Center and peer institutions has been awarded a $5.75 million grant from the National Cancer Institute to study the correlation between obesity, inflammation and pancreatic cancer. The scientists hope their findings may help people avoid getting this cancer.
NCCN Foundation Awards Leading Young Investigators Advancing Cancer Research for Adults and Children
NCCN and the NCCN Foundation announce five new recipients for the 10th annual NCCN Foundation Young Investigator Awards (YIA) Program, overseen by the NCCN Oncology Research Program (ORP)
Roswell Park Team Proposes Strategy for Making Pancreatic Tumors Respond to Checkpoint Inhibition
A possible new strategy for treating pancreatic cancer highlights the promise of collaboration between experts in both precision medicine and immunology. The findings from a team led by Agnieszka Witkiewicz, MD, and Erik Knudsen, PhD, at Roswell Park Comprehensive Cancer Center and published today in the journal Gut suggest a combination treatment approach that can make some breakthrough immunotherapy drugs effective for more patients with pancreatic cancer.
On the Run to Fight Pancreatic Cancer
Polly’s Run is on a mission to end pancreatic cancer. The annual fundraiser is held each year in honor of Polly Rogers, whose best friends and three sons started the 5K run-walk event after she died in 2009. This year, the event will be held virtually.
Study points to obesity as driver of pancreatic cancer
A new study led by Yale Cancer Center (YCC) researchers has demonstrated in mice that hormones released from the pancreas itself can advance pancreatic cancer — and that weight loss can stop this process in its early stages. The research was published today in the journal Cell.
How Surgeons Are Working to Improve Outcomes for Patients with Pancreatic Cancer
While researchers pursue scientific insights into the pancreatic cancer and develop new therapeutic approaches, surgeons on the front line of patient care are also working hard to improve outcomes.
Hari Nathan, M.D., Ph.D., an assistant professor of surgery at Michigan Medicine, explains.
Rush Earns National Center of Excellence for Pancreatic Cancer Designation
The National Pancreatic Foundation’s National Center of Excellence for Pancreatic Cancer designation is earned by hospitals that demonstrate the multi-disciplinary approach, social support and advanced research resources needed to treat this devastating disease.
Cedars-Sinai to Study How Fat May Promote Cancer Spread to Liver
A diagnosis of pancreatic or colon cancer often sparks dread about the disease’s likely next destination: the liver. That’s because liver metastasis is a leading cause of death in these patients. A Cedars-Sinai scientific team has been awarded a $9.1 million grant by the National Cancer Institute to study this often-fatal process, with the goal of understanding how cancer spreads to the liver and finding ways to block it.
Does Lung Damage Speed Pancreatic Cancer?
High levels of CO2 in the body, due to chronic respiratory disorders, may exacerbate pancreatic cancer, making it more aggressive and resistant to therapy.
U-M Team Sheds New Light on the Role of Regulatory T Cells in Pancreatic Cancer
A multidisciplinary Michigan Medicine team is shedding new light on the role of regulatory T cells in pancreatic cancer — and, in mouse models, have uncovered a new potential target to improve immunotherapy approaches to the deadly disease.
Shedding light on pancreatic neuroendocrine tumors
The University of Chicago Medicine’s Xavier Keutgen, MD, one of the few surgeons in the country with advanced expertise in extensive removal of neuroendocrine tumors, talks about this rare disease.
The Medical Minute: Progress slow against pancreatic cancer
Researchers are still trying to find ways of catching pancreatic cancer early – or better yet, preventing it altogether. Meantime, here’s what patients need to know.
Updated Genetic Screening Guidelines Published by National Comprehensive Cancer Network Feature Emerging Evidence on Personalized Medicine
NCCN Guidelines for Genetic/Familial Risk Assessment: Breast, Ovarian, and Pancreatic updated with new and expanded sections on risk assessment and management related to three major cancer types.
‘Magic bullet’ takes aim at pancreatic cancer
Every day, more than 1200 people worldwide are told they have pancreatic cancer. Within 12 months, 80 per cent of them will have succumbed to the disease.
One-two punch drug combination offers hope for pancreatic cancer therapy
Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified a combination of two anti-cancer compounds that shrank pancreatic tumors in mice—supporting the immediate evaluation of the drugs in a clinical trial. U.S. Food and Drug Administration (FDA)–approved versions of the compounds are used today to treat certain leukemias and solid tumors, including melanoma. The study was published in Nature Cell Biology.
Atlantic Health System Cancer Care Enrolling Patients in Innovative Pancreatic Cancer Clinical Trials
November is national Pancreatic Cancer Awareness month. This year alone, more than 56,000 Americans will be diagnosed with pancreatic cancer. Pancreatic tumors are particularly aggressive and hard to treat “due to a mutational profile that makes it resistant to therapies that work better for other tumor types,” explains Angela Alistar, MD, medical director of GI oncology at Morristown Medical Center. Dr. Alistar, an internationally known expert on pancreatic cancer, is now enrolling patients in five clinical trials aimed at pancreatic cancer.
Vaccine to Block Digestive Hormone May Slow Growth of Pancreatic Cancer
New research suggests a vaccine that blocks a digestive hormone may slow the spread of pancreatic cancer, potentially increasing survival rates. The study, published ahead of print in the American Journal of Physiology—Gastrointestinal and Liver Physiology, was chosen as an APSselect article for October.
MD Anderson study confirms protein as potential cause of most common type of pancreatic cancer
An oncogene, UPS21, has been confirmed as a frequently amplified gene in pancreatic ductal adenocarcinoma, the most common and often lethal form of pancreatic cancer. The discovery could lead to new treatment options.
Nerves Could be Key to Pancreatic Cancer Spread
A couple of molecules that nerve cells use to grow during development could help explain why the most common pancreatic cancers are so difficult to contain and for patients to survive